EA200501262A1 - Композиция с пролонгированным высвобождением венлафаксина - Google Patents

Композиция с пролонгированным высвобождением венлафаксина

Info

Publication number
EA200501262A1
EA200501262A1 EA200501262A EA200501262A EA200501262A1 EA 200501262 A1 EA200501262 A1 EA 200501262A1 EA 200501262 A EA200501262 A EA 200501262A EA 200501262 A EA200501262 A EA 200501262A EA 200501262 A1 EA200501262 A1 EA 200501262A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prolonged
venlafaxin
issues
composition
venlafaxine
Prior art date
Application number
EA200501262A
Other languages
English (en)
Other versions
EA011579B1 (ru
Inventor
Фьялар Йоханнссон
Биркир Арнасон
Original Assignee
Актавис Груп Хф.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS6710A external-priority patent/IS6710A/is
Priority claimed from IS7143A external-priority patent/IS7143A/is
Application filed by Актавис Груп Хф. filed Critical Актавис Груп Хф.
Publication of EA200501262A1 publication Critical patent/EA200501262A1/ru
Publication of EA011579B1 publication Critical patent/EA011579B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к таблетированным композициям с пролонгированным высвобождением венлафаксина. Показано, что Коллидон SR является превосходным агентом для пролонгированного высвобождения венлафаксина, который является чрезвычайно растворимым лекарством.
EA200501262A 2003-02-07 2004-02-09 Композиция с пролонгированным высвобождением венлафаксина EA011579B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS6710A IS6710A (is) 2003-02-07 2003-02-07 Venlafaxín samsetningar með seinkaða losun
IS7143A IS7143A (is) 2004-02-05 2004-02-05 Venlafaxín samsetningar með seinkaða losun
PCT/IS2004/000003 WO2004069228A2 (en) 2003-02-07 2004-02-09 Sustained release formulations of venlafaxine

Publications (2)

Publication Number Publication Date
EA200501262A1 true EA200501262A1 (ru) 2006-04-28
EA011579B1 EA011579B1 (ru) 2009-04-28

Family

ID=32852478

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501262A EA011579B1 (ru) 2003-02-07 2004-02-09 Композиция с пролонгированным высвобождением венлафаксина

Country Status (6)

Country Link
US (1) US20060246132A1 (ru)
EP (1) EP1596837A2 (ru)
EA (1) EA011579B1 (ru)
IS (1) IS8011A (ru)
NO (1) NO20054157L (ru)
WO (1) WO2004069228A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377473A1 (pl) * 2002-11-28 2006-02-06 Themis Laboratories Private Limited Sposób produkcji mikropeletek o przedłużonym uwalnianiu zawierających chlorowodorek wenlafaksyny
CZ20033294A3 (cs) * 2003-12-03 2005-06-15 Zentiva, A.S. Potahovaná tableta s obsahem venlafaxinu nebo jeho solí s řízeným uvolňováním
WO2005074895A1 (en) * 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
CZ307916B6 (cs) * 2017-05-08 2019-08-21 mcePharma s. r. o. Orodispergovatelná tableta s biodostupným kurkuminem a její použití

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
DE60038698T2 (de) * 1999-12-23 2009-05-07 Pfizer Products Inc., Groton Hydrogel-gesteuerte dosierungsform
EP1474123A1 (en) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Controlled release pharmaceutical formulation containing venlafaxine
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride

Also Published As

Publication number Publication date
EP1596837A2 (en) 2005-11-23
WO2004069228A2 (en) 2004-08-19
NO20054157D0 (no) 2005-09-07
WO2004069228A3 (en) 2004-09-16
US20060246132A1 (en) 2006-11-02
NO20054157L (no) 2005-11-03
EA011579B1 (ru) 2009-04-28
IS8011A (is) 2005-09-06

Similar Documents

Publication Publication Date Title
CL2018003398A1 (es) Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).
CR10157A (es) Compuestos químicos
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
AR052238A1 (es) Formulacion de tabletas estables
AR055441A1 (es) Formulacion novedosa
TW200716119A (en) A solid pharmaceutical dosage formulation
MX2007015424A (es) Formulaciones ungueales topicas.
BRPI0509184A (pt) composições farmacêuticas
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
MEP3608A (en) Modified-release tablet of bupropion hydrochloride
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
UY30472A1 (es) Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones.
WO2007019439A3 (en) Block copolymer compositions and uses thereof
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
WO2008073863A3 (en) Preparation and utility of substituted allylamines
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
GT200500268A (es) Inhibidores de la adenilato ciclasa soluble
BRPI0518172A (pt) prevenção de infecções verticais com endoparasitas
EA200501262A1 (ru) Композиция с пролонгированным высвобождением венлафаксина